Top 10 Tolcapone (Tasmar) Generic Manufacturers in Israel
The pharmaceutical industry in Israel has experienced significant growth in recent years, driven by a robust research and development ecosystem and a strong emphasis on generic drug production. As of 2023, the global generic drug market is expected to reach approximately $500 billion, with a significant portion attributed to high-demand medications like Tolcapone (Tasmar), used primarily in the treatment of Parkinson’s disease. In Israel, the pharmaceutical sector is a key player, contributing around 2.5% to the nation’s GDP, and the country exports pharmaceuticals worth over $1 billion annually. This report delves into the top ten manufacturers producing Tolcapone generics in Israel, highlighting their market performance and significance.
1. Teva Pharmaceutical Industries Ltd.
Teva is the largest pharmaceutical company in Israel and one of the leading generic drug manufacturers globally. With a production volume of over 20 billion doses annually, Teva holds about 25% of the global generic market share. The company offers a generic version of Tolcapone, which is pivotal for patients with Parkinson’s disease.
2. Perrigo Company plc
Perrigo, headquartered in Israel, focuses on over-the-counter and prescription pharmaceuticals, including generics. The company reported a revenue of $4.5 billion in 2022, with a growing share in the generic segment. Its Tolcapone generic has been well-received, contributing significantly to its portfolio.
3. Kamada Ltd.
Kamada specializes in biopharmaceuticals and has expanded its offerings to include generic drugs. In 2022, Kamada reported a revenue of approximately $100 million, with plans to increase its generic offerings. The company’s Tolcapone product plays a crucial role in its growth strategy.
4. Dexcel Pharma Technologies Ltd.
Dexcel is a prominent player in the Israeli pharmaceutical market, focusing on generic and proprietary products. With a revenue of $300 million in 2022, Dexcel has established a strong position in the generic Tolcapone market, catering to local and international demands.
5. InnoPharma Ltd.
InnoPharma is known for its expertise in developing generic formulations. The company has seen a production increase of 15% year-on-year, with its Tolcapone generic gaining traction in the market. Its focus on quality and compliance has made it a trusted name among healthcare providers.
6. Neopharm Group Ltd.
Neopharm Group is a leading distributor and manufacturer of pharmaceuticals in Israel, with a 10% market share in the generic segment. In 2022, the company’s revenue reached $500 million, with its Tolcapone generic being pivotal for patients seeking affordable treatment options.
7. Taro Pharmaceutical Industries Ltd.
Taro is a well-established pharmaceutical company that produces a wide range of generic medications. With a market capitalization of approximately $1.1 billion, Taro has made significant contributions to the Tolcapone market, ensuring accessibility for patients in need.
8. B. Braun Melsungen AG (Israel Division)
B. Braun is a global healthcare company with a significant presence in Israel. The Israel division focuses on generics, including Tolcapone, and has reported steady growth in sales, reflecting a growing demand for its products.
9. Chiasma, Inc.
Chiasma has been focusing on innovative treatments and generics. With a revenue of around $50 million in 2022, its Tolcapone generic is part of a broader strategy to diversify its offerings in the competitive pharmaceutical landscape.
10. Medison Pharma Ltd.
Medison is a leading Israeli pharmaceutical company specializing in generics and biosimilars. In 2022, it reported revenues of $250 million, with its generic Tolcapone contributing to enhanced patient access to essential medications.
Insights and Trends
The generic pharmaceutical market in Israel is poised for continued growth, driven by increasing demand for cost-effective treatment options and the aging population. As the global generic drug market is expected to expand at a CAGR of 7.5% from 2023 to 2030, Israeli manufacturers are likely to capitalize on this trend. A significant increase in R&D investments is anticipated, which will enhance the production capabilities of companies, particularly in high-demand areas such as neurological disorders. The focus on biosimilars and complex generics, including Tolcapone, is expected to shape the future landscape of the Israeli pharmaceutical market, ensuring that companies remain competitive in a rapidly evolving industry.
Related Analysis: View Previous Industry Report
